China's Nanjing Sinolife H1 profit falls on higher selling and distribution expenses

Nanjing Sinolife United

24/08/2026 11:54

Overview
China health supplements maker's H1 revenue rose 18% yr/yr
Profit for the period declined to RMB10.3 mln from RMB15.3 mln a year earlier
Company did not declare an interim dividend for the period

Outlook
Nanjing Sinolife United will deepen cross-border e-commerce across Douyin, Tmall and JD.com in H2 2026
Good Health will increase R&D spending and launch products focused on functional segmentation and precise ingredients

Result Drivers
REVENUE GROWTH - Revenue rose 18% yr/yr to RMB392.3 mln in H1
HIGHER OPERATING COSTS - Selling and distribution expenses rose sharply, contributing to lower profit despite higher gross profit

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 392.3 mln
 

Analyst Coverage
The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 1 three months ago

Reuters Recommended Reads
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth
Aug 24 - Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Aug 21 - China's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distribution

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)